Inpharmus

Inpharmus İnovatif çözümleri sağlıkla buluşturuyoruz!

Women play a central role in healthcare systems around the world, yet their representation in leadership and research do...
08/03/2026

Women play a central role in healthcare systems around the world, yet their representation in leadership and research does not fully reflect their impact.

On International Women’s Day, we recognize the contributions of women across science, healthcare, and innovation while highlighting the importance of advancing gender equity across the sector.

Supporting inclusive research environments and equitable leadership opportunities is essential for building stronger health systems and improving patient outcomes.

HealthcareLeadership

28/02/2026

Every child deserves a healthy life.

Today, on February 28, Rare Disease Day, we’re listening to Prof. Dr. Emel Cabı Ünal share valuable insights on rare diseases.

Let’s raise awareness!

“Rare” doesn’t mean “less important.”Millions of people worldwide live with rare diseases, each needing early diagnosis,...
28/02/2026

“Rare” doesn’t mean “less important.”

Millions of people worldwide live with rare diseases, each needing early diagnosis, proper treatment, and above all, to be seen and understood.

Awareness is about making the invisible visible. Empathy is about people, not statistics.

At Inpharmus, we transform scientific excellence into meaningful solutions, developing innovative and accessible therapies that improve the lives of those living with rare diseases.

27/02/2026

What you know about Rare Diseases… Fact or Myth? Our MSL team answers!

26/02/2026

30 million, 1 in 2,000, 5 years, 72%, 3 times higher… These are not just statistics; they represent delayed diagnoses, prolonged uncertainty, genetic realities, and an invisible emotional burden.

We are marking Rare Disease Day this week. On this occasion, we initiated awareness with a simple question: Guess the number. Because sometimes the most powerful way to make realities visible is to spark curiosity. And curiosity leads to understanding.

Individually, rare diseases may be uncommon; collectively, they represent a significant and urgent global health priority. Limited treatment options and complex patient journeys require strong scientific commitment and sustained innovation.

At Inpharmus, we are committed to developing innovative and accessible therapies for rare diseases, transforming scientific excellence into meaningful solutions that improve patients’ lives.

Because behind every number, there is a patient waiting and a family holding on to hope.

-Patients should consult healthcare professionals for diagnosis and treatment decisions.

25/02/2026

We are declaring 2026 as Inpharmus’ “Momentum Year.”

In this special interview with our CEO, İsmet İnce, we explored how we are advancing across the MERAT region; spanning Türkiye, Saudi Arabia, and Russia with one unified vision, one shared energy, and one strategic mindset. As we transform our regional strength into an integrated powerhouse, we are building an agile, bold, and innovation-driven growth model.

As a company focused on rare diseases, our ambition goes beyond expansion. We are committed to redefining patient journeys, addressing unmet medical needs, and creating lasting impact across the region.

On our path to achieving a $1 billion valuation, becoming a unicorn, and reaching $500 million in revenue by 2030, our strategy is clear: to push boundaries with a Star & Speed-driven culture, amplify our impact, and help shape the future of healthcare.

The risk of infection in immunocompromised patient populations represents one of the most sensitive aspects of the treat...
23/02/2026

The risk of infection in immunocompromised patient populations represents one of the most sensitive aspects of the treatment process. In these patients, infections can directly impact not only the clinical course but also the continuity of therapy.

Therefore, current clinical approaches prioritize early risk identification and the planning of preventive and supportive strategies under physician supervision and in line with individual patient needs.

Antiviral approaches shaped by scientific guidelines play a critical role in maintaining this delicate balance. A holistic perspective contributes to a safer and more sustainable treatment journey for immunocompromised patients.

Guided by a strong sense of clinical responsibility, Inpharmus continues to work on science-based approaches aimed at addressing the evolving needs of immunosuppressed patients.

In certain rare diseases, the immune system may shift from a protective role to an uncontrolled inflammatory response.Co...
18/02/2026

In certain rare diseases, the immune system may shift from a protective role to an uncontrolled inflammatory response.

Conditions such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) illustrate how excessive immune activation can lead to multiorgan damage and life-threatening outcomes.

This uncontrolled inflammation can be difficult to recognize, often mimicking sepsis, and delays in identification may significantly increase mortality risk. For this reason, timely recognition and appropriate control of the immune response are critical components of disease management in rare inflammatory conditions. Scientific, evidence-based approaches aim to support patient safety and treatment continuity in these complex clinical settings.

Inpharmus focuses on advancing patient-centered, science-driven approaches in the management of severe inflammatory conditions associated with rare diseases.

Inpharmus is committed to creating value in healthcare through a science-based approach. In the context of Childhood Can...
15/02/2026

Inpharmus is committed to creating value in healthcare through a science-based approach. In the context of Childhood Cancer Day on 15 February, we highlight the importance of science-driven knowledge and awareness around childhood cancers, while continuing to contribute to the healthcare ecosystem guided by science.

Developing drugs for rare diseases is challenging: small patient populations, limited data, and high R&D costs. Orphan d...
12/02/2026

Developing drugs for rare diseases is challenging: small patient populations, limited data, and high R&D costs. Orphan drugs help overcome these hurdles and address unmet medical needs. Inpharmus focuses on patient-centric solutions grounded in scientific evidence.

Chemotherapy is a cornerstone of oncology treatment; however, its side effects can challenge patients’ quality of life a...
09/02/2026

Chemotherapy is a cornerstone of oncology treatment; however, its side effects can challenge patients’ quality of life and treatment adherence.

Supportive approaches used alongside chemotherapy and under physician supervision aim to help patients cope with the challenges encountered during the treatment process.

A holistic approach in oncology focuses not only on treatment protocols, but also on the patient’s entire journey, placing safety and standards of care at its core.

Guided by scientific evidence, Inpharmus develops patient-centered solutions that prioritize patient safety and standards of care within the oncology care pathway.

Address

Esentepe, Büyükdere Caddesi Kanyon Ofis Bloğu No: 185 Kat: 14, 34394 Levent/Şişli/Şişli/Istanbul
Istanbul
34000

Website

Alerts

Be the first to know and let us send you an email when Inpharmus posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category